Literature DB >> 34619049

Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales.

Patricia J Simner1, Stephan Beisken2, Yehudit Bergman1, Michael Ante2, Andreas E Posch2, Pranita D Tamma3.   

Abstract

The objective of this study was to identify putative mechanisms contributing to baseline cefiderocol resistance among carbapenem-resistant Enterobacterales (CRE). We evaluated 56 clinical CRE isolates with no previous exposure to cefiderocol. Cefiderocol and comparator agent minimum inhibitory concentrations (MICs) were determined by broth microdilution. Short-read and/or long-read whole genome sequencing was pursued. Cefiderocol nonwild type (NWT; i.e., MICs ≥4 mg/L) CRE were compared with species-specific reference genomes and with cefiderocol wild type (WT) CRE isolates to identify genes or missense mutations, potentially contributing to elevated cefiderocol MICs. A total of 14 (25%) CRE isolates met cefiderocol NWT criteria. Of the 14 NWT isolates, various β-lactamases (e.g., carbapenemases in Klebsiella pneumoniae and AmpC β-lactamases in Enterobacter cloacae complex) in combination with permeability defects were associated with a ≥ 80% positive predictive value in identifying NWT isolates. Unique mutations in the sensor kinase gene baeS were identified among NWT isolates. Cefiderocol NWT isolates were more likely to be resistant to colistin than WT isolates (29% vs. 0%). Our findings suggest that no consistent antimicrobial resistance markers contribute to baseline cefiderocol resistance in CRE isolates and, rather, cefiderocol resistance results from a combination of heterogeneous mechanisms.

Entities:  

Keywords:  carbapenem-resistant Enterobacterales; cefiderocol; mechanisms of resistance

Mesh:

Substances:

Year:  2021        PMID: 34619049      PMCID: PMC8885434          DOI: 10.1089/mdr.2021.0095

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  40 in total

Review 1.  Mechanisms of Polymyxin Resistance.

Authors:  Jennifer H Moffatt; Marina Harper; John D Boyce
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

2.  Risk Factors for Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Carriage Upon Pediatric Intensive Care Unit Admission.

Authors:  David X Li; Anna C Sick-Samuels; Nuntra Suwantarat; Rebecca G Same; Patricia J Simner; Pranita D Tamma
Journal:  Infect Control Hosp Epidemiol       Date:  2017-12-05       Impact factor: 3.254

3.  Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime.

Authors:  Ryan K Shields; Alina Iovleva; Ellen G Kline; Akito Kawai; Christi L McElheny; Yohei Doi
Journal:  Clin Infect Dis       Date:  2020-12-17       Impact factor: 9.079

4.  Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechols: study with beta-lactam antibiotics containing catechol and analogous groups.

Authors:  H Nikaido; E Y Rosenberg
Journal:  J Bacteriol       Date:  1990-03       Impact factor: 3.490

5.  Antibacterial activity of BMS-180680, a new catechol-containing monobactam.

Authors:  J Fung-Tomc; K Bush; B Minassian; B Kolek; R Flamm; E Gradelski; D Bonner
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.

Authors:  James A Karlowsky; Meredith A Hackel; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; Daniel F Sahm
Journal:  Int J Antimicrob Agents       Date:  2018-11-22       Impact factor: 5.283

Review 7.  Aminoglycoside modifying enzymes.

Authors:  Maria S Ramirez; Marcelo E Tolmasky
Journal:  Drug Resist Updat       Date:  2010-09-15       Impact factor: 18.500

Review 8.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

9.  Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.

Authors:  Kenneth V I Rolston; Baghat Gerges; Samuel Shelburne; Samuel L Aitken; Issam Raad; Randall A Prince
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 10.  The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol.

Authors:  Yasaman Taheri; Nataša Joković; Jelena Vitorović; Oliver Grundmann; Alfred Maroyi; Daniela Calina
Journal:  Front Pharmacol       Date:  2021-01-14       Impact factor: 5.810

View more
  3 in total

Review 1.  Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.

Authors:  Stamatis Karakonstantis; Maria Rousaki; Evangelos I Kritsotakis
Journal:  Antibiotics (Basel)       Date:  2022-05-27

2.  Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport.

Authors:  Casin Le; Camila Pimentel; Fernando Pasteran; Marisel R Tuttobene; Tomás Subils; Jenny Escalante; Brent Nishimura; Susana Arriaga; Aimee Carranza; Vyanka Mezcord; Alejandro J Vila; Alejandra Corso; Luis A Actis; Marcelo E Tolmasky; Robert A Bonomo; Maria Soledad Ramírez
Journal:  Biomedicines       Date:  2022-03-03

3.  New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.

Authors:  Dennis Nurjadi; Kaan Kocer; Quan Chanthalangsy; Sabrina Klein; Klaus Heeg; Sébastien Boutin
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.